Plus’ CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for centr ...